Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CutisPharma, a specialty pharmaceutical company, has received approval from the US Patent and Trademark Office for its patent regarding a container and kit for the preparation, storage and dispensing of compounded suppositories.
Subscribe to our email newsletter
Currently CutisPharma has First progesterone vaginal suppository unit-of-use prescription compounding kit product line available, which uses the patented container. The line includes First – progesterone VGS 25, 50, 100, 200 and 400 representing various strengths (mg).
The kits are made for a single patient and include pre-weighed progesterone, and suppository base, and the patented disposable container or mold for preparation, storage, and dispensing of the suppositories.
According to the company, a single national drug code number assigned for the entire kit aids the third party reimbursement process, reduces audit- related adjustments, and the use of these First kits facilitates compliance with USP Chapter <795>. This patented container, kit, and the method will also be used for future suppository compounding kits such as Boric acid, Morphine, and others.
Indu Muni, founder, chairman, and CEO of CutisPharma, said: “Our container and the method for suppository-compounding is user-friendly and time saving for a pharmacy. Our suppository mold is also customer friendly because the take-home molds are especially designed to not only maintain the integrity of each suppository once compounded, but also provide convenient dispensing tools.”